Cargando…

Bruguiera gymnorhiza (L.) Lam. at the Forefront of Pharma to Confront Zika Virus and Microbial Infections—An In Vitro and In Silico Perspective

The recent emergence of Zika virus (ZIKV) in Brazil and the increasing resistance developed by pathogenic bacteria to nearly all existing antibiotics should be taken as a wakeup call for the international authority as this represents a risk for global public health. The lack of antiviral drugs and e...

Descripción completa

Detalles Bibliográficos
Autores principales: Bibi Sadeer, Nabeelah, Haddad, Juliano G., Oday Ezzat, Mohammed, Desprès, Philippe, Abdallah, Hassan H., Zengin, Gokhan, Uysal, Ahmet, El Kalamouni, Chaker, Gallo, Monica, Montesano, Domenico, Mahomoodally, Mohamad Fawzi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510246/
https://www.ncbi.nlm.nih.gov/pubmed/34641314
http://dx.doi.org/10.3390/molecules26195768
_version_ 1784582531192979456
author Bibi Sadeer, Nabeelah
Haddad, Juliano G.
Oday Ezzat, Mohammed
Desprès, Philippe
Abdallah, Hassan H.
Zengin, Gokhan
Uysal, Ahmet
El Kalamouni, Chaker
Gallo, Monica
Montesano, Domenico
Mahomoodally, Mohamad Fawzi
author_facet Bibi Sadeer, Nabeelah
Haddad, Juliano G.
Oday Ezzat, Mohammed
Desprès, Philippe
Abdallah, Hassan H.
Zengin, Gokhan
Uysal, Ahmet
El Kalamouni, Chaker
Gallo, Monica
Montesano, Domenico
Mahomoodally, Mohamad Fawzi
author_sort Bibi Sadeer, Nabeelah
collection PubMed
description The recent emergence of Zika virus (ZIKV) in Brazil and the increasing resistance developed by pathogenic bacteria to nearly all existing antibiotics should be taken as a wakeup call for the international authority as this represents a risk for global public health. The lack of antiviral drugs and effective antibiotics on the market triggers the need to search for safe therapeutics from medicinal plants to fight viral and microbial infections. In the present study, we investigated whether a mangrove plant, Bruguiera gymnorhiza (L.) Lam. (B. gymnorhiza) collected in Mauritius, possesses antimicrobial and antibiotic potentiating abilities and exerts anti-ZIKV activity at non-cytotoxic doses. Microorganisms Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, Klebsiella pneumoniae ATCC 70603, methicillin-resistant Staphylococcus aureus ATCC 43300 (MRSA), Salmonella enteritidis ATCC 13076, Sarcina lutea ATCC 9341, Proteus mirabilis ATCC 25933, Bacillus cereus ATCC 11778 and Candida albicans ATCC 26555 were used to evaluate the antimicrobial properties. Ciprofloxacin, chloramphenicol and streptomycin antibiotics were used for assessing antibiotic potentiating activity. ZIKV(MC-MR766NIID) (ZIKV(GFP)) was used for assessing anti-ZIKV activity. In silico docking (Autodock 4) and ADME (SwissADME) analyses were performed on collected data. Antimicrobial results revealed that Bruguiera twig ethyl acetate (BTE) was the most potent extract inhibiting the growth of all nine microbes tested, with minimum inhibitory concentrations ranging from 0.19–0.39 mg/mL. BTE showed partial synergy effects against MRSA and Pseudomonas aeruginosa when applied in combination with streptomycin and ciprofloxacin, respectively. By using a recombinant ZIKV-expressing reporter GFP protein, we identified both Bruguiera root aqueous and Bruguiera fruit aqueous extracts as potent inhibitors of ZIKV infection in human epithelial A549 cells. The mechanisms by which such extracts prevented ZIKV infection are linked to the inability of the virus to bind to the host cell surface. In silico docking showed that ZIKV E protein, which is involved in cell receptor binding, could be a target for cryptochlorogenic acid, a chemical compound identified in B. gymnorhiza. From ADME results, cryptochlorogenic acid is predicted to be not orally bioavailable because it is too polar. Scientific data collected in this present work can open a new avenue for the development of potential inhibitors from B. gymnorhiza to fight ZIKV and microbial infections in the future.
format Online
Article
Text
id pubmed-8510246
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85102462021-10-13 Bruguiera gymnorhiza (L.) Lam. at the Forefront of Pharma to Confront Zika Virus and Microbial Infections—An In Vitro and In Silico Perspective Bibi Sadeer, Nabeelah Haddad, Juliano G. Oday Ezzat, Mohammed Desprès, Philippe Abdallah, Hassan H. Zengin, Gokhan Uysal, Ahmet El Kalamouni, Chaker Gallo, Monica Montesano, Domenico Mahomoodally, Mohamad Fawzi Molecules Article The recent emergence of Zika virus (ZIKV) in Brazil and the increasing resistance developed by pathogenic bacteria to nearly all existing antibiotics should be taken as a wakeup call for the international authority as this represents a risk for global public health. The lack of antiviral drugs and effective antibiotics on the market triggers the need to search for safe therapeutics from medicinal plants to fight viral and microbial infections. In the present study, we investigated whether a mangrove plant, Bruguiera gymnorhiza (L.) Lam. (B. gymnorhiza) collected in Mauritius, possesses antimicrobial and antibiotic potentiating abilities and exerts anti-ZIKV activity at non-cytotoxic doses. Microorganisms Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, Klebsiella pneumoniae ATCC 70603, methicillin-resistant Staphylococcus aureus ATCC 43300 (MRSA), Salmonella enteritidis ATCC 13076, Sarcina lutea ATCC 9341, Proteus mirabilis ATCC 25933, Bacillus cereus ATCC 11778 and Candida albicans ATCC 26555 were used to evaluate the antimicrobial properties. Ciprofloxacin, chloramphenicol and streptomycin antibiotics were used for assessing antibiotic potentiating activity. ZIKV(MC-MR766NIID) (ZIKV(GFP)) was used for assessing anti-ZIKV activity. In silico docking (Autodock 4) and ADME (SwissADME) analyses were performed on collected data. Antimicrobial results revealed that Bruguiera twig ethyl acetate (BTE) was the most potent extract inhibiting the growth of all nine microbes tested, with minimum inhibitory concentrations ranging from 0.19–0.39 mg/mL. BTE showed partial synergy effects against MRSA and Pseudomonas aeruginosa when applied in combination with streptomycin and ciprofloxacin, respectively. By using a recombinant ZIKV-expressing reporter GFP protein, we identified both Bruguiera root aqueous and Bruguiera fruit aqueous extracts as potent inhibitors of ZIKV infection in human epithelial A549 cells. The mechanisms by which such extracts prevented ZIKV infection are linked to the inability of the virus to bind to the host cell surface. In silico docking showed that ZIKV E protein, which is involved in cell receptor binding, could be a target for cryptochlorogenic acid, a chemical compound identified in B. gymnorhiza. From ADME results, cryptochlorogenic acid is predicted to be not orally bioavailable because it is too polar. Scientific data collected in this present work can open a new avenue for the development of potential inhibitors from B. gymnorhiza to fight ZIKV and microbial infections in the future. MDPI 2021-09-23 /pmc/articles/PMC8510246/ /pubmed/34641314 http://dx.doi.org/10.3390/molecules26195768 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bibi Sadeer, Nabeelah
Haddad, Juliano G.
Oday Ezzat, Mohammed
Desprès, Philippe
Abdallah, Hassan H.
Zengin, Gokhan
Uysal, Ahmet
El Kalamouni, Chaker
Gallo, Monica
Montesano, Domenico
Mahomoodally, Mohamad Fawzi
Bruguiera gymnorhiza (L.) Lam. at the Forefront of Pharma to Confront Zika Virus and Microbial Infections—An In Vitro and In Silico Perspective
title Bruguiera gymnorhiza (L.) Lam. at the Forefront of Pharma to Confront Zika Virus and Microbial Infections—An In Vitro and In Silico Perspective
title_full Bruguiera gymnorhiza (L.) Lam. at the Forefront of Pharma to Confront Zika Virus and Microbial Infections—An In Vitro and In Silico Perspective
title_fullStr Bruguiera gymnorhiza (L.) Lam. at the Forefront of Pharma to Confront Zika Virus and Microbial Infections—An In Vitro and In Silico Perspective
title_full_unstemmed Bruguiera gymnorhiza (L.) Lam. at the Forefront of Pharma to Confront Zika Virus and Microbial Infections—An In Vitro and In Silico Perspective
title_short Bruguiera gymnorhiza (L.) Lam. at the Forefront of Pharma to Confront Zika Virus and Microbial Infections—An In Vitro and In Silico Perspective
title_sort bruguiera gymnorhiza (l.) lam. at the forefront of pharma to confront zika virus and microbial infections—an in vitro and in silico perspective
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510246/
https://www.ncbi.nlm.nih.gov/pubmed/34641314
http://dx.doi.org/10.3390/molecules26195768
work_keys_str_mv AT bibisadeernabeelah bruguieragymnorhizallamattheforefrontofpharmatoconfrontzikavirusandmicrobialinfectionsaninvitroandinsilicoperspective
AT haddadjulianog bruguieragymnorhizallamattheforefrontofpharmatoconfrontzikavirusandmicrobialinfectionsaninvitroandinsilicoperspective
AT odayezzatmohammed bruguieragymnorhizallamattheforefrontofpharmatoconfrontzikavirusandmicrobialinfectionsaninvitroandinsilicoperspective
AT despresphilippe bruguieragymnorhizallamattheforefrontofpharmatoconfrontzikavirusandmicrobialinfectionsaninvitroandinsilicoperspective
AT abdallahhassanh bruguieragymnorhizallamattheforefrontofpharmatoconfrontzikavirusandmicrobialinfectionsaninvitroandinsilicoperspective
AT zengingokhan bruguieragymnorhizallamattheforefrontofpharmatoconfrontzikavirusandmicrobialinfectionsaninvitroandinsilicoperspective
AT uysalahmet bruguieragymnorhizallamattheforefrontofpharmatoconfrontzikavirusandmicrobialinfectionsaninvitroandinsilicoperspective
AT elkalamounichaker bruguieragymnorhizallamattheforefrontofpharmatoconfrontzikavirusandmicrobialinfectionsaninvitroandinsilicoperspective
AT gallomonica bruguieragymnorhizallamattheforefrontofpharmatoconfrontzikavirusandmicrobialinfectionsaninvitroandinsilicoperspective
AT montesanodomenico bruguieragymnorhizallamattheforefrontofpharmatoconfrontzikavirusandmicrobialinfectionsaninvitroandinsilicoperspective
AT mahomoodallymohamadfawzi bruguieragymnorhizallamattheforefrontofpharmatoconfrontzikavirusandmicrobialinfectionsaninvitroandinsilicoperspective